Publication date: Oct 01, 2024
COVID-19 is characterized by pronounced hypercytokinemia. The cytokine switch, marked by an imbalance between pro-inflammatory and anti-inflammatory cytokines, emerged as a focal point of investigation throughout the COVID-19 pandemic. However, the kinetics and temporal dynamics of cytokine release remain contradictory, making the development of new therapeutics difficult, especially in severe cases. This study collected serum samples from SARS-CoV-2 infected patients at 72 h intervals and monitored them for various cytokines at each timepoint until hospital discharge or death. Cytokine levels were analyzed based on time since symptom onset and patient outcomes. All cytokines studied prospectively were strong predictors of mortality, particularly IL-4 (AUC = 0. 98) and IL-1β (AUC = 0. 96). First-timepoint evaluations showed elevated cytokine levels in the mortality group (p < 0. 001). Interestingly, IFN-γ levels decreased over time in the death group but increased in the survival group. Patients who died exhibited sustained levels of IL-1β and IL-4 and increased IL-6 levels over time. These findings suggest cytokine elevation is crucial in predicting COVID-19 mortality. The dynamic interplay between IFN-γ and IL-4 highlights the balance between Th1/Th2 immune responses and underscores IFN-γ as a powerful indicator of immune dysregulation throughout the infection.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
disease | MESH | hypercytokinemia |
pathway | REACTOME | Release |
disease | MESH | death |
disease | IDO | symptom |
drug | DRUGBANK | Binetrakin |
drug | DRUGBANK | Isoxaflutole |
disease | MESH | infection |
drug | DRUGBANK | Coenzyme M |
disease | MESH | inflammation |
disease | IDO | process |
disease | MESH | clinical importance |
disease | IDO | production |
disease | MESH | viral diseases |
disease | MESH | cardiomyopathies |
disease | MESH | lung injury |
disease | IDO | role |
disease | MESH | fibrosis |
disease | IDO | cell |
disease | IDO | host |
drug | DRUGBANK | Angiotensin II |
disease | IDO | immune response |
disease | MESH | complications |
drug | DRUGBANK | Aspartame |
disease | IDO | blood |
disease | MESH | hypertension |
disease | MESH | Diabetes mellitus |
disease | MESH | Dyslipidemia |